Rarity & Risk of Secondary Hematologic Neoplasms after CAR T-cell Therapies.

Hamilton, Mark P; Alizadeh, Ash A

Hamilton, Mark P; Alizadeh, Ash A.

Afiliação

Hamilton MP; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Alizadeh AA; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA; Stanford Cancer Institute, Stanford University, Stanford, CA, 94305, USA; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, 94305, USA.

Transplant Cell Ther ; 30(10): 936-938, 2024 Oct.

Article em En | MEDLINE | ID: mdl-39326982

Assuntos

Neoplasias Hematológicas; Imunoterapia Adotiva; Humanos; Neoplasias Hematológicas/terapia; Imunoterapia Adotiva/efeitos adversos; Segunda Neoplasia Primária/etiologia; Receptores de Antígenos Quiméricos/imunologia

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoterapia Adotiva / Neoplasias Hematológicas Limite: Humans Idioma: En Revista: Transplant Cell Ther Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google